{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T10:26:11Z","timestamp":1779186371203,"version":"3.51.4"},"reference-count":32,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T00:00:00Z","timestamp":1740268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007886","name":"Dana-Farber Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Melphalan flufenamide (melflufen) plus dexamethasone is fully approved in Europe for patients with relapsed\/refractory multiple myeloma (RRMM) with \u2265\u20093 prior lines of therapy. We analyzed the efficacy and safety of melflufen in the real\u2010world setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this retrospective analysis, we examined baseline features, efficacy, and safety outcomes with melflufen plus dexamethasone in a cohort of 12 patients with heavily pre\u2010treated RRMM at the Dana\u2010Farber Cancer Institute, USA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients had received a median of 5.5 prior lines of therapy. Three patients (25%) had extramedullary disease, three (25%) cytogenetically high\u2010risk features, and five (42%) had received prior autologous stem cell transplantation. The overall response rate was 55% (complete response: three [27%], very good partial response: one [9%], partial response: two [18%] patients). Five patients (42%) had stable disease; one was non\u2010evaluable. Adverse events (AEs) were mostly hematologic and proved manageable; two patients had Grade 2 infections. Reasons for melflufen discontinuation were progressive disease (42%), drug withdrawal from the United States market (33%), AEs (17%), and sudden death (8%) unrelated to treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Consistent with clinical trial data, melflufen had an expected safety profile with manageable toxicity and clinically meaningful efficacy in patients with RRMM treated in the real\u2010world setting.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.14398","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T03:00:17Z","timestamp":1741230017000},"page":"982-989","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Outcomes of Melflufen Treatment in Patients With Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1111","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6346-3376","authenticated-orcid":false,"given":"Shahrier","family":"Hossain","sequence":"first","affiliation":[{"name":"Department of Pharmacy Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clifton","family":"Mo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Patches","sequence":"additional","affiliation":[{"name":"Department of Nursing and Patient Care Services Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Houry","family":"Leblebjian","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Goodrich","sequence":"additional","affiliation":[{"name":"Department of Nursing and Patient Care Services Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen","family":"Regan","sequence":"additional","affiliation":[{"name":"Department of Nursing and Patient Care Services Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"O'Neill","sequence":"additional","affiliation":[{"name":"Department of Nursing and Patient Care Services Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Noonan","sequence":"additional","affiliation":[{"name":"Department of Nursing and Patient Care Services Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7426-8865","authenticated-orcid":false,"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Laubach","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,2,23]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.247015"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.329"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2218543"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.46"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/341430"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061819"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.138"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1275329"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.11.016"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0142-9"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_239067"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3752"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18420"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2009.12.022"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/10611860310001647140"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103120"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14065"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2013.07.026"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-1843"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02259"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00381-1"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-177945"},{"key":"e_1_2_11_24_1","volume-title":"Pepaxti\u00ae Summary of Product Characteristics","year":"2022"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0141-0"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S295215"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.05.004"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30044-2"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17302"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283509"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283490"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T10:51:55Z","timestamp":1746528715000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,23]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1111\/ejh.14398"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14398","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,23]]},"assertion":[{"value":"2024-10-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}